Novartis’ cancer combination Tafinlar and Mekinist has been approved by the EMA for adjuvant treatment of advanced melanoma in order to prevent disease recurrence. The new indication – the third for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results